Physician profile
David Lee Steitz
NPI 1114021599
$1,299.00
in general payments reported to CMS, 2019-2025
16 companies · $40.83 in 2025
The $40.83 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $114 · 2021: $387 · 2022: $402 · 2023: $152 · 2024: $52.27 · 2025: $40.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $559.54 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $124.05 | 2022-2023 | Jornay Pm |
| Corium, LLC | $102.46 | 2022-2023 | Azstarys |
| Cranial Technologies, INC | $75.50 | 2019-2023 | Doc Band |
| Merck Sharp & Dohme LLC | $67.35 | 2021-2024 | Rotateq, Vaxneuvance, Gardasil |
| Kaleo, INC. | $61.41 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.84 | 2021-2022 | |
| Sanofi Pasteur INC. | $49.40 | 2022-2025 | |
| Pfizer INC. | $46.37 | 2019-2024 | |
| Adlon Therapeutics L.P. | $45.82 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $25.31 | 2023 | Dupixent |
| Organon LLC | $19.39 | 2021 | |
| Glaxosmithkline, LLC. | $18.68 | 2019 | |
| Seqirus USA INC | $18.32 | 2024 | Flucelvax |
| Alk-Abello, INC | $16.32 | 2025 | Neffy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $13.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Steitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.